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Abstract
Aims: Here we aimed to firstly investigate the role of miR-27a in proliferation and multidrug resistance of gastric
cancer cells.
Methods: The role of miR-27a in gastric cancer cells was detected using MTT assay, soft agar assay, flow cytometry
assay, nude mice assay, real-time PCR, western blot and reporter gene assay, etc.
Results: Down-regulation of miR-27a could inhibit porliferation of gastric cancer cells in vitro and in vivo. Down-
regulation of miR-27a could also confer sensitivity of drugs on gastric cancer cells, and might increase
accumulation and decrease releasing amount of adriamycin in gastric cancer cells. Down-regulation of miR-27a
could significantly decrease the expression of P-glycoprotein and the transcriptional activity of cyclin D1, and up-
regulate the expression of p21.
Conclusions: MiR-27a might play important roles in porliferation and drug resistance of gastric cancer. MiR-27a
might be considered as a useful target for cancer therapy.
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Introduction
Gastric cancer was one of the major causes of mortality
in the world, especially in Asi a nc o u n t r i e s .S of a r ,t h e
pathogenic mechanism underlying gastric carcinogenesis
was not fully elucidated.
MicroRNAs (miRNAs) were a class of 22-nucleotide
noncoding RNAs, which might function as regulators of
gene expression [1]. More and more evidences showed
that miRNAs might play important roles in various bio-
logical processes, including cell proliferation, apoptosis,
tumorigenesis and MDR of cancer [2]. So far, the func-
tions of gastric cancer related miRNAs were not clear.
MiR-27a might mediate drug resistance of esophageal
cancer cells through regulation of MDR1 and apoptosis
[3]. However, the role of miR-27a in gastric cancer was
not reported yet. To our knowledge, here we have firstly
investigated the role of miR-27a in proliferation and
multidrug resistance of gastric cancer cells.
Materials and methods
Cell culture
Human gastric cancer cell line, MKN45, was routinely
maintained in DMEM medium (GIBCO, Carlsbad, CA,
USA) supplemented with 10% fetal bovine serum at 37°
C in humidified air containing 5% carbon dioxide air
atmosphere.
MiRNA transfection
Cells were plated in plates and cultured for 16 h, and
then transfected with the antagomirs of miR-27a or con-
trol RNA (Lafayette, CO) as described previously [3].
Real-time PCR
Total RNAs from cells were extracted and cDNA synth-
esis and amplification were performed as described pre-
viously [4]. Primers were designed as: MDR1, forward:
5’-CCCATCATTGCAATAGCAGG-3’,r e v e r s e :5 ’-
TGTTCAAACTTCTGCTCCTGA-3’; cyclinD1, forward:
5’-GGAGCTGCTCCTGGTGAACA-3’, reverse: 5’-
TGTTGGGGCTCCTCAG GTTCA-3’; P21, forward:
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CACAAGGG TACAAGA-3’; P27, forward: 5’-CAAG-
TACGAGTGGCAAGAGG-3’,r e v e r s e :5 ’-GTAGAA
GAATCGTCGGTTGC-3’. Comparative real-time PCR
was performed in triplicate, including no-template con-
trols. Relative expression was calculated using the com-
parative Ct method.
Cell growth assay
Cells were seeded on a 96-well plate at 3 × 10
4 cells/well.
Each sample has four replicates. Viable cells were
counted by the MTT assay after 2, 4, 6, and 8 days.
Soft agar assay
Soft agar assay was performed as described previously
[5]. Each assay was performed in triplicate.
Tumor growth in nude mice
Female athymic nu/nu mice, 5-6 weeks of age, were
used in the experiment. The cells were resuspended in
D’Hanks solution, and 5 × 10
6 cells in 0.2 ml were
injected subcutaneously into the right flank of 4-week-
age mice. Experimental and control groups had at least
6 mice each. Tumors were measured twice weekly, and
the tumor volume was calculated.
In vitro drug sensitivity assay
Vincristine (VCR), adriamycin (ADR), cisplatin (CDDP)
and 5-fludrouracil (5-flu) were prepared before experi-
ment. Drug sensitivity was evaluated using MTT assay
as described previously [3].
Flow cytometry assay (FCM)
Fluorescence intensity of intracellular ADR was detected
by FCM as described previously [3].
Western blot
Cellular proteins were separated on SDS-PAGE gels, and
western blot was performed as described previously [3].
Reporter gene assay
The pGL3-cyclin D1 vector and the control vector were
prepared as described previously [3]. Briefly, 0.4 μgo f
reporter gene constructs was transfected into MKN45
cells using LipofectAMINE (Invitrogen) reagent accord-
ing to the manufacturer’s protocol. This transfection
was done concurrently with the transfection of the
antagomirs of miR-27a. Cells co-transfected with
scrambled antago-miR-NC served as controls.
Statistical analysis
All the data were presented as the mean ± SD. The sig-
nificance of differences was determined with Student’st
test or the c2t e s t .P < 0.05 was considered statistically
significant.
Results
Down-regulation of miR-27a inhibited the growth and
tumorigenecity of gastric cancer cells
As Figure 1A showed, MKN45 cells were transfected
with either the antagomirs of miR-27a or control RNA.
The antagomirs of miR-27a could significantly inhibit
the expression of miR-27a by almost 67% as compared
with that of control. Cell growth was assayed, and
down-regulation of miR-27a significantly inhibited pro-
liferation of MKN45 cells as compared with control (P <
0.05) (Figure 1B). MKN45 cells and their transfectants
were seeded in soft agar and colon formation was
assessed. As shown in Figure 1C, down-regulation of
miR-27a significantly inhibited the number of colonies
formed by gastric cancer cells. Tumorigenesis was found
profoundly decreased in miR-27a-downregulating cells
as compared with control groups (Figure 1D), suggesting
that down-regulation of miR-27a might inhibit the
growth of MKN45 cells in vitro and in vivo.
Down-regulation of miR-27a might reverse drug
resistance of gastric cancer cells
As shown in Table 1, the IC50 values of miR-27a antag-
omir cells for VCR, ADR and 5-flu were significantly
decreased as compared with control cells. The ADR
intracellular accumulation and releasing were explored
using FCM assay. As shown in Figure 2A, B, increased
accumulation and decreased releasing index of ADR of
miR-27a antagomir cells was observed as compared with
control cells (p < 0.05).
Effect of mir-27a on protein regulating proliferation and
drug resistance
The expression of P-glycoprotein, cyclin D1, p21 and p27
was detected in the gastric cancer cells using real-time PCR
(Figure 3) and western blot (Figure 4). Down-regulation of
miR-27a could significantly decrease the expression of P-
glycoprotein and cyclin D1, and up-regulate the expression
of p21. To evaluate whether cyclin D1 was a genuine target
of miR-27a, luciferase reporter assay was performed. As
shown in Figure 5, co-transfection of increasing amounts of
antagomirs of miR-27a with cyclin D1 reporter gene led to
significantly decrease in cyclin D1 promoter activity,
suggesting that miR-27a might target cyclin D1.
Discussion
Aberrant miRNA expression patterns had been described
in a variety of malignancies. MiRNAs might play impor-
tant roles in multiple developmental processes. MiR-27a
was widely expressed in cancer cells and might function
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angiogenesis [6-11]. In this study, we have firstly found
that miR-27a might play important roles in mediating
proliferation and drug resistance of gastric cancer.
To obtain a better model in which cells of the same
origin could be compared, we transfected MKN45 cells
with the antagomirs of miR-27a or control RNA. The
results of MTT assay and soft agar assay revealed that
down-regulation of miR-27a inhibited cell growth of
gastric cancer cells in vitro, which was consistent with
t h ed a t ao fn u d em i c ea s s a y .T h es t u d yw a sa i m e da t
investigating the effect of miR-27a on gastric cancer
cells and more importantly, examining the mechanisms
governing these effects. Here we clearly showed for the
Figure 1 ZNRD1 suppressed growth of gastric cancer cells in vitro and in vivo. The data represented the mean ± SD of three independent
experiments. A, Relative level of miR-27a in MKN45 cells after transfection. The mRNA level of the control cell (MKN45-control) was arbitrarily set
at 1, and the mRNA levels of miR-27a in MKN45-antagomir cells were normalized to the control.B, the growth rate of the cells was detected
using MTT assay. C, colony numbers of the cells were detected in soft agar. D, tumorigenicity of the cells in BALB/c nu/nu mice was detected.
The volumes of tumors were monitored at the indicated time.
Table 1 IC50 values (μg/mL) of drugs for gastric cancer cells
VCR ADR 5-Flu CDDP
MKN45 6.12 ± 0.22 6.41 ± 0.15 5.24 ± 0.11 5.11 ± 0.13
MKN45-control 5.81 ± 0.16 6.22 ± 0.11 4.88 ± 0.15 4.38 ± 0.26
MKN45-antagomir 1.68 ± 0.11
a 1.93 ± 0.12
a 1.79 ± 0.08
a 1.16 ± 0.07
a
Data were represented as mean ± SD of 3 independent experiments.
a p < 0.05 vs MKN45 and MKN45-control cells.
Zhao et al. Journal of Experimental & Clinical Cancer Research 2011, 30:55
http://www.jeccr.com/content/30/1/55
Page 3 of 5first time that miR-27a might mediate cell proliferation
by regulation of cyclin D1 and p21. Cyclin D1 might
play important roles in facilitating the transition from
G1 phase into S. The results of luciferase reporter assay
suggested that miR-27a might be a transcriptional regu-
lator of the cyclin D1 gene.
The results of MTT assay indicated that down-regula-
tion of miR-27a promoted drug sensitivity of gastric
cancer cells. ADR was then used as probe to evaluate
drug accumulation and retention in cancer cells. The
results of FCM showed that down-regulation of miR-
Figure 2 Effect of miR-27a on ADR intracellular accumulation
and releasing of MKN45 cells. A, Fluorescence intensity analysis of
intracellular ADR in cells; B, ADR releasing index of cells.
Figure 3 Effects of a miR-27a on expression of cyclin D1, P-gp,
p21 and p27 in gastric cancer cells. The mRNA level of the
samples treated with a control RNA was arbitrarily set at 1, and the
genes’ mRNA levels of the transfected cells were normalized to the
control.
Figure 4 Western blot analysis of cyclin D1, P-gp, p21 and p27
in gastric cancer cells. b-actin was used as an internal control.
Figure 5 The effect of antagomirs of miR-27a on cyclin D1
promoter activity. Luciferase reporter assay was detected by
cotransfection of this reporter gene (0.2 μg/well) with increasing
amounts of antagomirs of miR-27a (0.3, 0.6, and 1 nM) in MKN45
cells. Cells co-transfected with scrambled antago-miR-NC served as
controls.
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decreased ADR releasing index, indicating that miR-27a
had a direct or indirect function of pumping drug out of
cells. The results of real-time PCR and western blot
showed that miR-27a might mediate the expression of
P-gp, which might function as an ATP-dependent drug-
efflux pump.
Conclusions
In conclusion, down-regulation of miR-27a might inhibit
proliferation and drug resistance of gastric cancer cells
through regulation of P-gp, cyclin D1 and p21. MiR-27a
might be considered as a valuable target for cancer
therapy.
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